title: Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
abstract: The changes in viremia levels and the development of drug-related mutations were examined in 26 patients with symptomatic human immunodeficiency virus type 1 (HIV-1) infection participating in a randomized trial comparing alternating (A) and simultaneous (S) regimens of zidovudine and didanosine therapy. Patients on both arms had significant reduction in serum RNA copies from baseline throughout the 2 years of study. Significant differences between the two arms were demonstrated over the first 2-3 months of therapy. Analyses with nested polymerase chain reaction revealed that the emergence of the didanosine-related position 74 Leu-->Val mutation was significantly blocked in both regimens, while the zidovudine-related mutation at codon 215 was not affected. Determination of the overall durability of the antiviremic effect of the A and S regimens of zidovudine and didanosine and clinical implications of the results require further research.
authors.affiliation: Experimental Retrovirology Section, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: E
authors.initials: E
authors.lastname: Kojima
authors.forename: T
authors.initials: T
authors.lastname: Shirasaka
authors.forename: B D
authors.initials: BD
authors.lastname: Anderson
authors.forename: S
authors.initials: S
authors.lastname: Chokekijchai
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: S
authors.initials: S
authors.lastname: Broder
authors.forename: R
authors.initials: R
authors.lastname: Yarchoan
authors.forename: H
authors.initials: H
authors.lastname: Mitsuya
mesh_terms: D000328:Adult; D001483:Base Sequence; D018791:CD4 Lymphocyte Count; D003062:Codon / Q000235:genetics; D016049:Didanosine / Q000008:administration & dosage* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D015751:Genes, pol / Q000235:genetics; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation; D012367:RNA, Viral / Q000097:blood; D014766:Viremia / Q000188:drug therapy*; D015215:Zidovudine / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D003062:Codon; D016655:HIV Core Protein p24; D012367:RNA, Viral; D015215:Zidovudine; D016049:Didanosine